Michelle E Fullard1,2, Sharon X Xie3, Ken Marek4,5, Matthew Stern2,5, Danna Jennings6, Andrew Siderowf2,5, Allison W Willis2,3, Alice S Chen-Plotkin2. 1. Parkinson's Disease Research, Education, and Clinical Center (PADRECC), Philadelphia VA Medical Center, Philadelphia, Pennsylvania, USA. 2. Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 3. Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 4. Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA. 5. Parkinson's Associated Risk Study, New Haven, Connecticut, USA. 6. Eli Lilly and Company, New York, New York, USA.
Abstract
BACKGROUND: Lower vitamin D levels have been associated with manifest Parkinson's disease, prompting the hypothesis that vitamin D insufficiency or deficiency may increase risk for PD. OBJECTIVES: To evaluate vitamin D levels in a population at risk for developing PD. METHODS: Plasma vitamin D levels were measured in the Parkinson Associated Risk Syndrome Study, a cohort of asymptomatic individuals, some of whom are at high risk for PD. Vitamin D levels were compared between subjects at high risk for PD (hyposmia and dopamine transporter scan deficit) versus all others and examined for correlations with dopaminergic system integrity. RESULTS: Mean vitamin D levels did not differ between groups, with a level of 27.8 ng/mL (standard deviation = 12.0) in the high-risk group versus 24.7 ng/mL (standard deviation = 9.0) in all others (P = 0.09). Vitamin D levels did not associate with putaminal dopamine transporter uptake. CONCLUSIONS: Our data from the asymptomatic Parkinson Associated Risk Syndrome cohort do not support the hypothesis that chronic vitamin D insufficiency threatens dopaminergic system integrity, contributing to PD pathogenesis.
BACKGROUND: Lower vitamin D levels have been associated with manifest Parkinson's disease, prompting the hypothesis that vitamin Dinsufficiency or deficiency may increase risk for PD. OBJECTIVES: To evaluate vitamin D levels in a population at risk for developing PD. METHODS: Plasma vitamin D levels were measured in the Parkinson Associated Risk Syndrome Study, a cohort of asymptomatic individuals, some of whom are at high risk for PD. Vitamin D levels were compared between subjects at high risk for PD (hyposmia and dopamine transporter scan deficit) versus all others and examined for correlations with dopaminergic system integrity. RESULTS: Mean vitamin D levels did not differ between groups, with a level of 27.8 ng/mL (standard deviation = 12.0) in the high-risk group versus 24.7 ng/mL (standard deviation = 9.0) in all others (P = 0.09). Vitamin D levels did not associate with putaminal dopamine transporter uptake. CONCLUSIONS: Our data from the asymptomatic Parkinson Associated Risk Syndrome cohort do not support the hypothesis that chronic vitamin Dinsufficiency threatens dopaminergic system integrity, contributing to PD pathogenesis.
Authors: Lama M Chahine; Daniel Weintraub; Keith A Hawkins; Andrew Siderowf; Shirley Eberly; David Oakes; John Seibyl; Matthew B Stern; Kenneth Marek; Danna Jennings Journal: Mov Disord Date: 2015-08-21 Impact factor: 10.338
Authors: Danna Jennings; Andrew Siderowf; Matthew Stern; John Seibyl; Shirley Eberly; David Oakes; Kenneth Marek Journal: Neurology Date: 2014-10-08 Impact factor: 9.910
Authors: Andrew Siderowf; Danna Jennings; Shirley Eberly; David Oakes; Keith A Hawkins; Albert Ascherio; Matthew B Stern; Kenneth Marek Journal: Mov Disord Date: 2012-01-11 Impact factor: 10.338
Authors: Liyong Wang; Marian L Evatt; Lizmarie G Maldonado; William R Perry; James C Ritchie; Gary W Beecham; Eden R Martin; Jonathan L Haines; Margaret A Pericak-Vance; Jeffery M Vance; William K Scott Journal: Mov Disord Date: 2014-12-27 Impact factor: 10.338
Authors: Hongliu Ding; Kaltra Dhima; Kaitlin C Lockhart; Joseph J Locascio; Ashley N Hoesing; Karen Duong; Ana Trisini-Lipsanopoulos; Michael T Hayes; U Shivraj Sohur; Anne-Marie Wills; Brit Mollenhauer; Alice W Flaherty; Albert Y Hung; Nicte Mejia; Vikram Khurana; Stephen N Gomperts; Dennis J Selkoe; Michael A Schwarzschild; Michael G Schlossmacher; Bradley T Hyman; Lewis R Sudarsky; John H Growdon; Clemens R Scherzer Journal: Neurology Date: 2013-09-25 Impact factor: 9.910